Healthcare Cmo Market Scope And Analysis

  • Report Code : TIPRE00003263
  • Category : Life Sciences
  • No. of Pages : 150
Buy Now

Healthcare CMO Market Analysis Report 2024 to 2031

Buy Now

Healthcare CMO Market Report Healthcare CMO Market Size and Share Healthcare CMO Market Scope and Analysis

Healthcare CMO Market Report Scope

Report Attribute Details
Market size in 2023 US$ 138.24 Billion
Market Size by 2031 US$ 385.26 Billion
Global CAGR (2023 - 2031) 13.7%
Historical Data 2021-2022
Forecast period 2024-2031
Segments Covered By Service
  • Pharmaceutical Contract Manufacturing Services
  • Medical Device Contract Manufacturing Services
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Royal DSM
  • Catalent Inc
  • Boehringer Ingelheim International GmbH
  • Recipharm AB publ
  • Fareva
  • Lonza
  • Piramal Enterprises Ltd
  • Dr Reddy
    		•

    Healthcare CMO Market News and Recent Developments

    The healthcare CMO market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the healthcare CMO market are listed below:

    • Kühne Holding AG has entered into a definitive agreement to acquire pharma contract development and manufacturing organization Aenova Group from leading international investment firm BC Partners. As part of the transaction, BC Partners’ advised funds will reinvest alongside Kühne Holding AG and continue to support Aenova as a minority shareholder. Financial terms were not disclosed. The Aenova Group is one of the world's leading CDMOs (Contract Development and Manufacturing Organizations) in the pharmaceutical and healthcare industry. (BC Partners, News, April 2024)
    • Pharmascience, the largest Canadian-owned pharmaceutical company, announced a major US$ 120 million sterile injectable manufacturing facility expansion at its Candiac site. Following this important milestone, the company is now proud to announce the expansion of its contract development and manufacturing organization (CDMO) services with the creation of a new business unit dedicated to injectable products. (Pharmascience Inc., News, February 2024)
    • Danaher Corporation announced a definitive agreement to acquire privately-held Aldevron, for cash purchase price of approximately US$ 9.6 billion, Danaher expects to finance the acquisition using cash on hand and/or proceed from the issuance of commercial paper. (Danaher Corporation, Press Release, June 2021)

    Healthcare CMO Market Report Coverage and Deliverables

    The “Healthcare CMO Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

    • Healthcare CMO market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
    • Healthcare CMO market trends as well as market dynamics such as drivers, restraints, and key opportunities
    • Detailed PEST and SWOT analysis
    • Healthcare CMO market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
    • Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the healthcare CMO market
    • Detailed company profiles